Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation

Supporting evidence

• Evaluation report

• Draft guidance consultation committee papers (PDF 6.69 MB)

  Published:

  05 June 2024

• Final draft guidance committee papers (PDF 1.52 MB)

  Published:

  05 June 2024